All In Biotech

Drug Trial Radar · NCT06599658

COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

The Immunogenicity and Safety of COVID-19 and Influenza Vaccine Co-administration and Interval in Immunocompromised Hosts

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 660 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

660

Planned (sponsor's estimate)

Start

Nov 20, 2024

Primary completion

Jan 31, 2028

Study completion Mar 31, 2028

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Centre hospitalier de l'Université de Montréal (CHUM)
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with immunocompromising conditions (PLIC). The main questions it aims to answer are: 1. Is co-administration of seasonal inactivated influenza vaccine (IIV) with the most up-to-date recommended COVID-19 booster dose non-inferior in inducing a 1-month peak protective humoral response against COVID-19, compared to a strategy of sequential administration of COVID-19 booster dose followed by seasonal IIV given one month later? 2. Is the administration of the most up-to-date recommended COVID-19 booster doses at 3-month intervals superior at maintaining a longer term protective humoral immune response, compared to booster doses administered at 6-month intervals? Researchers will compare (1) COVID-19 and Influenza vaccines administered at Day 0 + COVID-19 Booster at a 3-month interval, (2) COVID-19 vaccine administered at Day 0 and Influenza vaccine administered at Day 28 + COVID-19 Booster at a 3-month interval, (3) COVID-19 and Influenza vaccines administered at Day 0 + COVID-19 Booster at a 6-month interval, and (4) COVID-19 vaccine administered at Day 0 and Influenza vaccine administered at Day 28 + COVID-19 Booster at a 6-month interval to see if median neutralization capacity of patient sera is non-inferior in the co- vs. sequential administration arms at 1-month after the initial COVID-19 booster and superior in the 3-month interval arms vs. the 6-month interval arms at 12 months after the initial COVID-19 booster. These outcomes will also be compared at 2-months for question 1 and 6-months for question 2. People living with immunocompromising conditions who take part in the trial will have blood samples drawn to verify immune response, be monitored for changes in clinical events and therapies, and complete questionnaires to verify adverse effects, quality of life and economic impact.

Conditions

  • COVID 19
  • Influenza
  • Rheumatoid Arthritis (RA)
  • Systemic Lupus Erthematosus
  • Inflammatory Bowel Disease
  • Solid Organ Transplant Recipients
  • Immunocompromised Host
  • People Living With HIV

Interventions

  • Inactivated influenza vaccine (IIV) at baselineBiological

    National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age at baseline

  • COVID-19 Vaccines at a 3-month intervalBiological

    Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 3-month interval

  • Inactivated influenza vaccine at Month 1Biological

    National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age 1-month following initial COVID-19 booster

  • COVID-19 Vaccines at a 6-month intervalBiological

    Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 6-month interval

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Median neutralization capacity against prevalent SARS-CoV-2 variantTime frame: At 1-month and 2-months following the initial COVID-19 booster dose for primary objective 1 and at 12-months and 6-months following initial COVID-19 booster dose for primary objective 2

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Maisonneuve -Rosemont Installation

    Montreal, Quebec, Canada · Active not recruiting

  • Centre hospitalier de l'Université de Montréal (CHUM)

    Montreal, Quebec, Canada · Recruiting

  • Research Institute of McGill University Health Centre

    Montreal, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.